Outlook Therapeutics, Inc. (OTLK)
Data as of , from SEC Form 4 filings.
Net insider buying (90d)Watch OTLK
See up to 3 months of OTLK. The 7-day demo opens the 1M and 3M ranges and puts OTLK on your watchlist.
Start 7-day demoLatest OTLK insider trades
About Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. files with the SEC under CIK 0001649989 and is classified as biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.
OTLK Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 7 | 5,650,952 | $2.60M |
| Grant or award | 3 | 810,078 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
OTLK insider transactions (Form 4)
5930 Form 4 filings on record, the earliest from Oct 3, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Kevin Michael Lundquist - Officer | Grant or award | Employee Stock Option (Right to Buy) | 500,000 | $0.00 | - | |
| Robert Charles Jahr - Officer | Open-market purchase | Common Stock | 151,515 | - footnote F1 | - | |
| Robert Charles Jahr - Officer | Open-market purchase | Warrants (right to buy) | 151,515 | - footnote F1 | - | |
| ||||||
| Ghiath M. Sukhtian - Director | Open-market purchase | Common Stock | 2,525,252 | $0.99 footnote F1 | $2.50M | |
| Ghiath M. Sukhtian - Director | Open-market purchase | Warrants (right to buy) | 2,525,252 | $0.00 footnote F1 | - | |
| ||||||
| Lawrence A. Kenyon - Officer | Open-market purchase | Common Stock | 101,010 | - footnote F1 | - | |
| Lawrence A. Kenyon - Officer | Open-market purchase | Warrants (right to buy) | 101,010 | - footnote F1 | - | |
| ||||||
 Faisal Ghiath Sukhtian - Director | Open-market purchase | Common Stock | 95,398 | $1.05 | $100K | |
| Lawrence A. Kenyon - Officer | Grant or award | Stock Option (Right to Buy) | 210,078 | $0.00 | - | |
| Robert Charles Jahr - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
 Yezan Munther Haddadin - Director | Open-market purchase | Common Stock | 29,000 | $0.83 | $24K | |
| Ghiath M. Sukhtian | Open-market purchase | Common Stock | 8,539,709 footnote F1 | $0.59 | $5.00M | |
| Ghiath M. Sukhtian | Other | Warrants (right to buy) | 3,458,571 | - footnote F4 | - | |
| Ghiath M. Sukhtian | Other | Warrants (right to buy) | 3,458,571 | - footnote F5 | - | |
| Ghiath M. Sukhtian | Open-market purchase | Warrants (right to buy) | 3,458,571 | - footnote F4 | - | |
| Ghiath M. Sukhtian | Open-market purchase | Warrants (right to buy) | 3,458,571 | - footnote F5 | - | |
| Ghiath M. Sukhtian | Other | Warrants (right to buy) | 8,571,428 | - footnote F6 | - | |
| Ghiath M. Sukhtian | Open-market purchase | Warrants (right to buy) | 8,571,428 | - footnote F6 | - | |
| ||||||
| Faisal Ghiath Sukhtian - Director | Open-market purchase | Common Stock | 122,174 | $0.41 | $50K | |
| Yezan Munther Haddadin - Director | Open-market purchase | Common Stock | 34,000 | $0.44 | $15K | |
 Randy H. Thurman - Director | Open-market purchase | Common Stock | 5,000 | $0.43 | $2K | |
 Kurt J. Hilzinger - Director | Open-market purchase | Common Stock | 400,000 | $0.44 | $177K | |
| Andong Huang - Director | Grant or award | Stock Option (Right to Buy) | 286,734 | $0.00 | - | |
| Andong Huang - Director | Grant or award | Stock Option (Right to Buy) | 53,316 | $0.00 | - | |
 Julia A. Haller - Director | Grant or award | Stock Option (Right to Buy) | 286,734 | $0.00 | - | |
| Julia A. Haller - Director | Grant or award | Stock Option (Right to Buy) | 58,648 | $0.00 | - | |
| Yezan Munther Haddadin - Director | Grant or award | Stock Option (Right to Buy) | 286,734 | $0.00 | - | |
| Yezan Munther Haddadin - Director | Grant or award | Stock Option (Right to Buy) | 95,969 | $0.00 | - | |
| Faisal Ghiath Sukhtian - Director | Grant or award | Stock Option (Right to Buy) | 286,734 | $0.00 | - | |
| Faisal Ghiath Sukhtian - Director | Grant or award | Stock Option (Right to Buy) | 117,296 | $0.00 | - | |
 Gerd Auffarth - Director | Grant or award | Stock Option (Right to Buy) | 286,734 | $0.00 | - | |
| Gerd Auffarth - Director | Grant or award | Stock Option (Right to Buy) | 58,648 | $0.00 | - | |
| Julian S. Gangolli - Director | Grant or award | Stock Option (Right to Buy) | 286,734 | $0.00 | - | |
| Randy H. Thurman - Director | Grant or award | Stock Option (Right to Buy) | 286,734 | $0.00 | - | |
| Kurt J. Hilzinger - Director | Grant or award | Stock Option (Right to Buy) | 286,734 | $0.00 | - | |
| Kurt J. Hilzinger - Director | Grant or award | Stock Option (Right to Buy) | 90,638 | $0.00 | - | |
| Robert Charles Jahr - Officer | Grant or award | Stock Option (Right to Buy) | 800,000 | $0.00 | - | |
| Julia A. Haller | Grant or award | Stock Option (Right to Buy) | 56,636 | $0.00 | - | |
| Julia A. Haller | Grant or award | Stock Option (Right to Buy) | 47,232 | $0.00 | - | |
| Julia A. Haller | Grant or award | Stock Option (Right to Buy) | 12,082 | $0.00 | - | |
| Andong Huang | Grant or award | Stock Option (Right to Buy) | 56,636 | $0.00 | - | |
| Andong Huang | Grant or award | Stock Option (Right to Buy) | 23,509 | $0.00 | - | |
| Andong Huang | Grant or award | Stock Option (Right to Buy) | 10,984 | $0.00 | - | |
| Yezan Munther Haddadin | Grant or award | Stock Option (Right to Buy) | 56,636 | $0.00 | - | |
| Yezan Munther Haddadin | Grant or award | Stock Option (Right to Buy) | 132,293 | $0.00 | - | |
| Yezan Munther Haddadin | Grant or award | Stock Option (Right to Buy) | 19,771 | $0.00 | - | |
| Faisal Ghiath Sukhtian | Grant or award | Stock Option (Right to Buy) | 56,636 | $0.00 | - | |
| Faisal Ghiath Sukhtian | Grant or award | Stock Option (Right to Buy) | 134,430 | $0.00 | - | |
| Faisal Ghiath Sukhtian | Grant or award | Stock Option (Right to Buy) | 19,771 | $0.00 | - | |
| Gerd Auffarth | Grant or award | Stock Option (Right to Buy) | 56,636 | $0.00 | - | |
| Gerd Auffarth | Grant or award | Stock Option (Right to Buy) | 29,493 | $0.00 | - | |
| Gerd Auffarth | Grant or award | Stock Option (Right to Buy) | 12,082 | $0.00 | - | |
| Julian S. Gangolli | Grant or award | Stock Option (Right to Buy) | 56,636 | $0.00 | - | |
| Julian S. Gangolli | Grant or award | Stock Option (Right to Buy) | 71,169 | $0.00 | - | |
| Randy H. Thurman | Grant or award | Stock Option (Right to Buy) | 56,636 | $0.00 | - | |
| Randy H. Thurman | Grant or award | Stock Option (Right to Buy) | 89,549 | $0.00 | - | |
| Kurt J. Hilzinger | Grant or award | Stock Option (Right to Buy) | 56,636 | $0.00 | - | |
| Kurt J. Hilzinger | Grant or award | Stock Option (Right to Buy) | 105,151 | $0.00 | - | |
| Kurt J. Hilzinger | Grant or award | Stock Option (Right to Buy) | 18,672 | $0.00 | - | |
Item 3.01
Item 8.01
Item 5.02, 9.01
Item 2.02, 9.01
OTLK insider trading FAQ
What is the latest insider trade for OTLK?
Outlook Therapeutics, Inc. (OTLK) had 7 insider filings in the last 90 days, with the most recent on 2026-09-02. The full record for OTLK runs to 30 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying OTLK stock?
7 insider purchases of OTLK were filed in the last 90 days, totaling $2.60M.
How many insiders are selling OTLK stock?
No insider sales of OTLK were filed in the last 90 days.
Where can I see OTLK SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects OTLK Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Kevin Michael Lundquist view on EDGAR
- - Robert Charles Jahr view on EDGAR
- - Ghiath M. Sukhtian view on EDGAR
- - Lawrence A. Kenyon view on EDGAR
- - Faisal Ghiath Sukhtian view on EDGAR
- - Lawrence A. Kenyon view on EDGAR
- - Robert Charles Jahr view on EDGAR
- - Yezan Munther Haddadin view on EDGAR
- - Ghiath M. Sukhtian view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where OTLK's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow OTLK with a 7-day demo
- OTLK on your watchlist
- Every OTLK Form 4 filing on record
- Up to 3 months of OTLK price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
